Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data
Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): A. Zaidi, J.P. Solar Vasconcelos, T. do Amaral Miranda, S. Gill, K.P.S. Raghav, J.M. Loree
Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826000567?dgcid=rss_sd_all
Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826000567?dgcid=rss_sd_all
“Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data.” ESMO Gastrointestinal Oncology.
@article{article44738,
title = {Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826000567?dgcid=rss_sd_all}
}